Yale Biomedical Engineers Develop Nanoparticle Brain Cancer Treatment
In a recent study, Yale researchers developed a new way to more effectively treat brain cancer using nanoparticles. Led by biomedical engineering professor Mark Saltzman and radiology professor Ranjit Bindra, the team first administered mice with medulloblastoma, a brain cancer that predominantly affects children. Then, they developed and used drug-carrying nanoparticles to deliver treatment over a sustained period of time. The study showed that mice who received this treatment lived significantly longer than mice who received traditional brain cancer treatment. “This treatment is a way to directly target tumor cells in the central nervous system (CNS) with the potential to minimize toxic therapies, like radiation therapy to the CNS, as well as high doses of systemically administered chemotherapies,” Bindra told the News.Source: Yale Daily News
YHN SPORE collaborators Receive $13.3 Million Renewal of Grant to Address Cancer Health Disparities
YHN SPORE collaborators at FCCC have received a five-year, $13.3 million competitive grant renewal from the National Cancer Institute (NCI), part of the National Institutes of Health, to address cancer health disparities.Source: Fox Chase
Nanoparticles Deliver Treatment Directly to Tumors of Deadly Brain Cancer
Using nanoparticles administered directly into the cerebrospinal fluid (CSF), a research team has developed a treatment that may overcome significant challenges in treating a particularly deadly brain cancer. The researchers, led by professors Mark Saltzman, PhD, and Ranjit Bindra, MD, PhD, administered to mice with medulloblastoma a treatment that features specially designed drug-carrying nanoparticles. The study, published in Science Translational Medicine, showed that mice who received this treatment lived significantly longer than mice in the control group.
New Yale Cancer Center Research Highlighted at Top Radiation Oncology Conference
Yale Cancer Center physicians, scientists, and trainees from Yale School of Medicine present new findings at the 65th annual American Society for Radiation Oncology (ASTRO) meeting from October 1-4 in San Diego, California.
Yale Pathology Joins Office of Health Equity Research in Community Listening Session
Several members of Yale Pathology recently joined members of the Office of Health Equity Research (OHER) at Yale School of Medicine at a community listening session to understand how to approach people about participating in medical research.
Combination exhibits ‘impressive’ activity in HPV-negative head and neck cancer
“HPV-negative disease is one aera of head and neck cancer where we haven’t made much progress,” investigator Barbara Burtness, MD, chief translational research officer for Yale Cancer Center and Smilow Cancer Hospital, as well as associate cancer center director for translational research at Yale Cancer Center, told Healio. “These cancers respond to chemotherapy and EGFR inhibitors, but the duration of response has not been great. “There has been a breakthrough with the introduction of immune checkpoint inhibitors, but the majority of patients progress on those as well,” added Burtness, a Healio | HemOnc Today Editorial Board Member. “When we move into late lines of therapy, not many agents have shown promise. That’s one of the reasons people are so excited about this study.”Source: Healio
The Room Where It Happens: Addressing Diversity, Equity, and Inclusion in NCTN Clinical Trial Leadership
Many multicenter randomized clinical trials in oncology are conducted through the National Clinical Trials Network (NCTN), an organization consisting of five cooperative groups.Source: Journal of the National Cancer Institute
Impact of Changing Landscape for Patients With Cancer Who Are Prescribed Opioids
In response to the opioid epidemic in the United States, interventions to prevent over-prescribing and misuse of opioids were enacted at institutional, state, and federal levels. To assess how changes in the prescribing landscape affected patients, a research team from the Yale COPPER Center examined the rates of both new and persistent opioid prescribing in patients with cancer as well as in patients without cancer, utilizing data from SEER-Medicare.
Dr. Park on the Role of Radiation Therapy in NSCLC
Henry S. Park, MD, MPH, discusses the importance of considering radiation therapy in patients with non–small cell lung cancer and how this therapeutic approach can work in concert with targeted therapy and other systemic therapies.Source: OncLive
Yale Cancer Center and Smilow Cancer Hospital Physicians and Scientists Presenting Latest Advances at 2023 ASCO Annual Meeting
Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 2nd to June 6th at McCormick Place in Chicago, Illinois. This year’s scientific program will feature more than 2,900 abstracts, covering all major diseases and research areas, including breast, lung, head and neck, gynecological, prostate, and gastric cancers.